Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Azathioprine in Moderate-to-Severe Atopic Dermatitis
NCT05969730Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of baricitinib + topical corticosteroid in atopic dermatitis (AD) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoint: Eczema Area and Severity Index at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
baricitinib + topical corticosteroid
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05969730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969730.